Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

Leukemia

Volumn 21, Issue 8, 2007, Pages 1802-1811

  Tarella, C ^a   Zanni, M ^a   Di Nicola, M ^b   Patti, C ^c   Calvi, R ^c   Pescarollo, A ^e   Zoli, V ^f   Fornari, A ^g   Novero, D ^g   Cabras, A ^h   Stella, M ^c   Comino, A ^d   Remotti, D ^f   Ponzoni, M ^e   Caracciolo, D ^a   Ladetto, M ^a   Magni, M ^b   Devizzi, L ^b   Rosato, R ^g   Boccadoro, M ^a   Bregni, M ^e   Corradini, P ^b   Gallamini, A ^d   Majolino, I ^f   Mirto, S ^c   Gianni, A M ^b   more..

^a Dipto di Med e Oncol Sperimentale   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTEROCOLITIS; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; NEUROTOXICITY; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 34447626101     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404781     Document Type: Article

References (57)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346; 235-242.
2. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al., MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
3. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
4. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23 4117-4126.
5. Tarella C, Gianni AM. BMT for Lymphoma CR1. Curr Opin Oncol 2005; 17: 99-105.
6. Gisselbrecht C, Mounier N. Managing large cell lymphoma. Symposium article. Ann Oncol 2006; 17 (Suppl 4): Iv4-iv11.
7. Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, et al. German High-Grade Non-Hodgkin Lymphoma Study Group. Dose-escaleted CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006; 107: 3058-3064.
8. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006; 107: 4623-4627.
9. Voso MT, Pantel G, Weis M, Schmidt P, Martin S, Moos M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoa. Br J Haematol 2000; 109: 729-735.
10. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
11. Flinn IW, O'Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628-632.
12. Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001; 15: 1941-1949.
13. Belhadj K, Delfau-Larue MH, Elgnaoui T, Beaujean F, Beaumont JL, Pautas C et al. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: A single institution study. Ann Oncol 2004; 15: 504-510.
14. Gianni AM, Bonadonna G. High dose chemoradiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery ? Eur J Cancer Clin Oncol 1989; 25: 1027-1030.
15. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G. Granulocyte-macrophage colony-stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 1989; ii: 580-585.
16. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
17. Tarella C, Cuttica A, Caracciolo D, Zallio F, Ricca I, Bergui L et al. High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: Long-term analysis and future developments. Ann Hematol 2001; 80 (Suppl 3): B123-B126, Review.
18. Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S et al. High-dose sequential chemotherapy and peripheral blood progenitor cell (PBPC) autografting in refractory/relapsed Hodgkin's lymphoma: A multicenter study of the Intergruppo Italiano Linfomi (lil) showing prolonged disease-free survival in patients treated at first relapse. Cancer 2003; 97: 2748-2759.
19. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
20. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
21. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002; 33: 968-974.
22. Pileri SA, Dirnhofer S, Went P, Ascani S, Sabattini E, Marafioti T et al. Diffuse large B-cell lymphoma: One or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002; 41: 482-509.
23. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
24. Weinstein HJ, Cassady JR, Levey R. Long term results of the APO protocol (vincristine, doxorubicin, and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1983; 1: 537-541.
25. Tarella C, Zallio F, Caracciolo D, Cuttica A, Corradini P, Gavarotti P et al. High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBSC) autograft in 113 lymphoma patients: High tolerability with reversible cardiotoxicity. Leukemia 2001; 15: 256-263.
26. Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: Evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21: 401-407.
27. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
28. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
29. Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P et al. High-dose Ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: An indication for patients at risk for low mobilization. Bone Marrow Transplant 2002; 30: 725-732.
30. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
31. Shipp MA. Prognostic factors in Aggressive Non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 1994; 83: 1165-1173.
32. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al., German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
33. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury. J Clin Oncol 1999; 17: 423-429.
34. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in pdor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
35. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.
36. Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: A meta-analysis. Haematologica 2003; 88: 1304-1315.
37. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
38. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphoma: Hematologic recovery and cost. Ann Intern Med 1997; 126: 600-607.
39. Majolino I, Pearce R, Taghipour G, Goldstone AH. Peripheral blood stem cell transplantation versus autologous bone marrow transplantation in Hodgkin's lymphoma: A new matched-pair analysis of the European group for blood and marrow transplantation registry data. J Clin Oncol 1997; 15: 509-517.
40. Salles G, Coiffier B. Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Baillieres Best Pract Res Clin Haematol 1999; 12: 151-169.
41. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22-30.
42. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69.
43. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000.
44. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 1486-1488.
45. Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002; 100 1104-1105.
46. Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 2003; 36: E47-e49.
47. Sirvent-Von Bueltzingsloewen A, Sirvent N, Morand P, Cassuto JP. Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (Rituximab) for a post transplantation Epstein - Barr virus-linked lymphoma. Med Pediatr Oncol 2003; 40: 408-409.
48. Isobe Y, Sugimoto K, Shiraki Y, Nishitani M, Koike K, Oshimi K. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol 2004; 77: 370-373.
49. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulmitrating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-191.
50. Cuttica A, Zallio F, Ladetto M, Di Nicola M, Caracciolo D, Magni M et al. Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: Evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. Cancer 2003; 98: 983-992.
51. Vitolo U, Bertini M, Brusamolino E, Cavallero GB, Comotti B, Gallo E et al. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992; 10: 219-227.
52. Yan Y, Chan WC, Weisenburger DD, Anderson JR, Bast MA, Vose JM et al. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol 1995; 13: 1336-1342.
53. Perea G, Altes A, Bellido M, Aventin A, Bordes R, Ayats R et al. Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). Histopathology 2004; 45: 268-274.
54. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
55. van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135-4142.
56. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-783.
57. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240-2247.